- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CDSCO Panel Approves AstraZeneca's protocol amendment proposal for COPD drug Tozorakimab
![CDSCO Panel Approves AstraZenecas protocol amendment proposal for COPD drug Tozorakimab CDSCO Panel Approves AstraZenecas protocol amendment proposal for COPD drug Tozorakimab](https://medicaldialogues.in/h-upload/2024/06/17/750x450_241275-astrazeneca-50.webp)
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major AstraZeneca's Proposal for the amendment of the Protocol titled "Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations".
This came after the firm presented protocol amendment version 3.0 dated 26.03.2024 protocol no. D9180C00008. This is a phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled extension study to evaluate the long-term efficacy and safety of Tozorakimab in participants with chronic obstructive pulmonary disease (COPD) with a history of exacerbations (PROSPERO).
Tozorakimab is a human monoclonal antibody that neutralizes interleukin (IL)-33. IL-33 is a broad-acting epithelial “alarmin” cytokine upregulated in the lung tissue of patients with chronic obstructive pulmonary disease (COPD).
Tozorakimab directly neutralizes IL-33red inflammatory activities at the ST2 receptor. The IL-33red–tozorakimab complex prevents the oxidation of IL-33, IL-33ox–RAGE/EGFR signalling and epithelial dysfunction.
At the recent SEC meeting for pulmonary, the expert panel reviewed the protocol amendment version 3.0 dated 26.03.2024 protocol no. D9180C00008.
After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.
Also Read:Bristol Myers Squibb India Gets CDSCO Panel Nod to Study anticancer drug Mezigdomide
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751